Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma

Published:February 09, 2009DOI:


      To evaluate the relationship of hormone (estrogen receptor α, estrogen receptor β, progesterone receptor) and growth factor receptor (insulin-like growth factor receptor, human epidermal growth factor receptor 2) expression with disease progression in uterine carcinosarcoma.

      Study Design

      Immunohistochemistry was performed on tissue arrays using standard methodology. Differences between groups were evaluated by the Wilcoxon rank-sum test. Interactions between tumor stage and receptor expression were determined by linear trend analysis.


      Compared with normal endometrium, carcinosarcomas exhibited low estrogen receptor α and progesterone receptor expression (all P < .01), but overexpressed estrogen receptor β (P = .02). Estrogen receptor β expression increased in advanced stage disease (P = .02). Insulin-like growth factor receptor expression was lower in carcinosarcoma compared with normal endometrium (P = .01). Human epidermal growth factor receptor 2 expression was elevated and increased with disease progression (P < .01).


      In uterine carcinosarcoma, estrogen receptor β expression is elevated and increases with disease progression, whereas estrogen receptor α and progesterone receptor are suppressed. Human epidermal growth factor receptor 2 expression is increased, whereas insulin-like growth factor receptor is lower than in normal endometrium. These data support a potential role for estrogen receptor β in disease progression via crosstalk with human epidermal growth factor receptor 2.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Silverberg S.G.
        • Major F.J.
        • Blessing J.A.
        • et al.
        Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases.
        Int J Gynecol Pathol. 1990; 9: 1-19
        • Bitterman P.
        • Chun B.
        • Kurman R.J.
        The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: a clinicopathologic and immunohistochemical study.
        Am J Surg Pathol. 1990; 14: 317-328
        • Amant F.
        • Cadron I.
        • Fuso L.
        • et al.
        Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
        Gynecol Oncol. 2005; 98: 274-280
        • de Brito P.A.
        • Silverberg S.G.
        • Orenstein J.M.
        Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases.
        Hum Pathol. 1993; 24: 132-142
        • Gorai I.
        • Yanagibashi T.
        • Taki A.
        • et al.
        Uterine carcinosarcoma is derived from a single stem cell: an in vitro study.
        Int J Cancer. 1997; 72: 821-827
        • Iwasa Y.
        • Haga H.
        • Konishi I.
        • et al.
        Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
        Cancer. 1998; 82: 512-519
        • Watanabe M.
        • Shimizu K.
        • Kato H.
        • et al.
        Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case.
        Gynecol Oncol. 2001; 82: 563-567
        • McCluggage W.G.
        Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.
        Int J Gynecol Cancer. 2002; 12: 687-690
        • Amant F.
        • Vloeberghs V.
        • Woestenborghs H.
        • et al.
        ERBB-2 gene overexpression and amplification in uterine sarcomas.
        Gynecol Oncol. 2004; 95: 583-587
        • Livasy C.A.
        • Reading F.C.
        • Moore D.T.
        • Boggess J.F.
        • Lininger R.A.
        EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
        Gynecol Oncol. 2006; 100: 101-106
        • Rice L.W.
        • Stone R.L.
        • Xu M.
        • et al.
        Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed mullerian tumors.
        Am J Obstet Gynecol. 2006; 194 (discussion 1126-8): 1119-1126
        • Hubalek M.
        • Ramoni A.
        • Mueller-Holzner E.
        • Marth C.
        Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
        Gynecol Oncol. 2004; 95: 264-266
        • Deligdisch L.
        • Kalir T.
        • Cohen C.J.
        • de Latour M.
        • Le Bouedec G.
        • Penault-Llorca F.
        Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
        Gynecol Oncol. 2000; 78: 181-186
        • Evans M.J.
        • Langlois N.E.
        • Kitchener H.C.
        • Miller I.D.
        Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus?.
        Int J Gynecol Cancer. 1995; 5: 310-313
        • Cohen I.
        Endometrial pathologies associated with postmenopausal tamoxifen treatment.
        Gynecol Oncol. 2004; 94: 256-266
        • Swerdlow A.J.
        • Jones M.E.
        Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
        J Natl Cancer Inst. 2005; 97: 375-384
        • McCluggage W.G.
        • Abdulkader M.
        • Price J.H.
        • et al.
        Uterine carcinosarcomas in patients receiving tamoxifen: a report of 19 cases.
        Int J Gynecol Cancer. 2000; 10: 280-284
        • Goldman N.A.
        • de Los Angeles M.M.
        • Jones J.G.
        • Goldberg G.L.
        Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.
        Obstet Gynecol. 2005; 105: 1278-1280
        • Pelletier G.
        • El-Alfy M.
        Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs.
        J Clin Endocrinol Metab. 2000; 85: 4835-4840
        • Shang Y.
        Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
        Nat Rev Cancer. 2006; 6: 360-368
        • Shang Y.
        • Brown M.
        Molecular determinants for the tissue specificity of SERMs.
        Science. 2002; 295: 2465-2468
        • Girault I.
        • Lerebours F.
        • Amarir S.
        • et al.
        Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
        Clin Cancer Res. 2003; 9: 1259-1266
        • Song R.X.
        • Zhang Z.
        • Chen Y.
        • Bao Y.
        • Santen R.J.
        Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.
        Endocrinology. 2007; 148: 4091-4101
        • Shou J.
        • Massarweh S.
        • Osborne C.K.
        • et al.
        Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
        J Natl Cancer Inst. 2004; 96: 926-935
        • Huang G.S.
        • Chiu L.G.
        • Gebb J.S.
        • et al.
        Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.
        Gynecol Oncol. 2007; 107: 513-517
        • Jazaeri A.A.
        • Nunes K.J.
        • Dalton M.S.
        • Xu M.
        • Shupnik M.A.
        • Rice L.W.
        Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression.
        Oncogene. 2001; 20: 6965-6969
        • Zafrakas M.
        • Kostopoulou E.
        • Dragoumis K.
        • Mikos T.
        • Papadimas J.
        • Bontis J.
        Expression of estrogen receptors alpha and beta in two uterine mesenchymal tumors after prolonged tamoxifen therapy: report of two cases.
        Eur J Gynaecol Oncol. 2004; 25: 530-533
        • McCampbell A.S.
        • Broaddus R.R.
        • Loose D.S.
        • Davies P.J.
        Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium.
        Clin Cancer Res. 2006; 12: 6373-6378
        • Koehler K.F.
        • Helguero L.A.
        • Haldosen L.A.
        • Warner M.
        • Gustafsson J.A.
        Reflections on the discovery and significance of estrogen receptor beta.
        Endocr Rev. 2005; 26: 465-478
        • Cimbaluk D.
        • Rotmensch J.
        • Scudiere J.
        • Gown A.
        • Bitterman P.
        Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
        Gynecol Oncol. 2007; 105: 138-144
        • Massarweh S.
        • Osborne C.K.
        • Creighton C.J.
        • et al.
        Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
        Cancer Res. 2008; 68: 826-833
        • Gunter M.J.
        • Hoover D.R.
        • Yu H.
        • et al.
        A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.
        Cancer Epidemiol Biomarkers Prev. 2008; 17: 921-929
        • Schulten H.J.
        • Wolf-Salgo J.
        • Grundker C.
        • Gunawan B.
        • Fuzesi L.
        Characterization of a newly established uterine carcinosarcoma cell line featuring the sarcomatous phenotype of the tumor in vitro.
        Int J Gynecol Cancer. 2008; 18: 339-344